MetALD: New Perspectives on an Old Overlooked Disease

Simple item page
dc.catalogadorjca
dc.contributor.authorAyares, Gustavo
dc.contributor.authorDíaz, Luis Antonio
dc.contributor.authorIdalsoaga, Francisco
dc.contributor.authorAlkhouri, Naim
dc.contributor.authorNoureddin, Mazen
dc.contributor.authorBataller, Ramon
dc.contributor.authorLoomba, Rohit
dc.contributor.authorArab, Juan Pablo
dc.contributor.authorArrese, Marco
dc.date.accessioned2025-05-06T17:31:26Z
dc.date.available2025-05-06T17:31:26Z
dc.date.issued2025
dc.description.abstractMetabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) are the major contributors to the liver disease burden globally. The rise in these conditions is linked to obesity, type 2 diabetes, metabolic syndrome and increased alcohol consumption. MASLD and ALD share risk factors, pathophysiology and histological features but differ in their thresholds for alcohol use, and the ALD definition does not require the presence of metabolic dysfunction. A recent multi-society consensus overhauled the nomenclature of liver steatosis and introduced the term MetALD to describe patients with metabolic dysfunction who drink more than those with MASLD and less than those with ALD. This new terminology aims to enhance the understanding and management of liver disease but poses challenges, such as the need to accurately measure alcohol consumption in research and clinical practice settings. Recent studies show that MetALD has significant implications for patient management, as it is associated with increased mortality risks and more severe liver outcomes compared to MASLD alone. MetALD patients face increased risks of liver disease progression, cancer and cardiovascular disease. The diagnosis of MetALD involves the adequate quantification of alcohol use through standardised questionnaires and/or biomarkers as well as proper assessment of liver disease stage and progression risk using non-invasive tools including serologic markers, imaging, elastography techniques and genetic testing. Effective management requires addressing both metabolic and alcohol-related factors to improve outcomes. This review intends to provide a comprehensive overview of MetALD, covering pathogenesis, potential diagnostic approaches, management strategies and emerging therapies.
dc.fechaingreso.objetodigital2025-05-06
dc.fuente.origenWOS
dc.identifier.doi10.1111/liv.70017
dc.identifier.eissn1478-3231
dc.identifier.issn1478-3223
dc.identifier.urihttps://doi.org/10.1111/liv.70017
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/104027
dc.identifier.wosidWOS:001458848500001
dc.issue.numero5
dc.language.isoen
dc.nota.accesocontenido completo
dc.publisherWILEY
dc.revistaLiver International
dc.rightsacceso abierto
dc.subjectAlcoholic liver disease
dc.subjectAlcohol-related liver disease
dc.subjectAmetabolic dysfunction-associated steatotic liver disease
dc.subjectCirrhosisalcoholic cirrhosis
dc.subjectMASLD
dc.subjectNAFLD
dc.subjectNon-alcoholic fatty liver disease
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleMetALD: New Perspectives on an Old Overlooked Disease
dc.typereseña
dc.volumen45
sipa.trazabilidadWOS;2025-04-12
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Liver International - 2025 - Ayares - MetALD New Perspectives on an Old Overlooked Disease.pdf
Size:
1.45 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas